Pliant THERAPEUTICS, Inc. (PLRX) intrinsic value & 10-year financials
Pliant THERAPEUTICS, Inc. (PLRX) has a Graham intrinsic value of $230.44 per share. At $0.90 on Oct 17, 2026, the stock trades 100% below that value. Over the last 8 fiscal years revenue shrank 59.2% a year to $0, with an average return on invested capital of -51.7%.
- Graham intrinsic value
- $230.44
- Share price (Oct 17, 2026)
- $0.90
- Price vs Graham value
- 100% below
- Market cap
- $55.2M
- Revenue (FY2025)
- $0
- Revenue growth (8-yr CAGR)
- -59.2%
- ROIC (10-yr avg)
- -51.7%
- Free cash flow (FY2025)
- -$128.7M
PLRX 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$149.3M | -$2.43 | -$128.7M | — | -68.6% |
| FY2024 | $0 | -$210.3M | -$3.47 | -$159.4M | — | -64.1% |
| FY2023 | $1.6M | -$161.3M | -$2.75 | -$117.3M | -11654.7% | -51.6% |
| FY2022 | $9.7M | -$123.3M | -$2.94 | -$96.4M | -1313.4% | -57.1% |
| FY2021 | $7.6M | -$97.3M | -$2.71 | -$77.4M | -1288.1% | -50.7% |
| FY2020 | $41.8M | -$41.5M | -$1.95 | -$38.8M | -99.6% | -17.9% |
| FY2019 | $57.1M | -$631.0K | -$0.32 | -$3.7M | -2.2% | — |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
PLIANT THERAPEUTICS, INC. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
PLIANT THERAPEUTICS, INC. has historically struggled to out-earn its cost of capital, averaging just -51.7% ROIC.
PLIANT THERAPEUTICS, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, PLIANT THERAPEUTICS, INC. is modeled at -59.2% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $230.44 per share.